As much as one-quarter of the world's population has been latently infected with Mycobacterium tuberculosis, with an increased risk of developing tuberculosis disease at some point during their lifetime, especially among those who are immunocompromised. Therefore, administration of tuberculosis preventive treatment to individuals with M tuberculosis infection is crucial for tuberculosis control. Historically, tuberculosis preventive treatment consisted of daily isoniazid monotherapy for 6 to 9 months (6–9H).